{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:49:54Z","timestamp":1793555394361,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["PROMETEO2018\/141"],"award-info":[{"award-number":["PROMETEO2018\/141"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBER CB06\/04\/0071"],"award-info":[{"award-number":["CIBER CB06\/04\/0071"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBER EHD19PI03"],"award-info":[{"award-number":["CIBER EHD19PI03"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/0312"],"award-info":[{"award-number":["PI14\/0312"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007136","name":"Secretar\u00eda de Estado de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI2018-096748-B-I00"],"award-info":[{"award-number":["RTI2018-096748-B-I00"]}],"id":[{"id":"10.13039\/501100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007136","name":"Secretar\u00eda de Estado de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF2015-67678-R"],"award-info":[{"award-number":["SAF2015-67678-R"]}],"id":[{"id":"10.13039\/501100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU13\/00151"],"award-info":[{"award-number":["FPU13\/00151"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU16\/05896"],"award-info":[{"award-number":["FPU16\/05896"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Juan Esplugues"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2019,8,15]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Liver fibrosis constitutes a major health problem worldwide due to its rapidly increasing prevalence and the lack of specific and effective treatments. Growing evidence suggests that signalling through cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways regulates liver fibrosis and regeneration. Rilpivirine (RPV) is a widely used anti-HIV drug not reported to produce hepatotoxicity. We aimed to describe the potential hepatoprotective effects of RPV in different models of chronic liver injury, focusing on JAK-STAT signalling regulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The effects of RPV on hepatic steatosis, inflammation and fibrogenesis were studied in a nutritional mouse model of non-alcoholic fatty liver disease, carbon tetrachloride-induced fibrosis and bile duct ligation-induced fibrosis. Primary human hepatic stellate cells (hHSC) and human cell lines LX-2 and Hep3B were used to investigate the underlying molecular mechanisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>RPV exerted a clear anti-inflammatory and antifibrotic effect in all the in vivo models of liver injury employed, and enhanced STAT3-dependent proliferation in hepatocytes and apoptosis in HSC through selective STAT1 activation. These results were reproduced in vitro; RPV undermined STAT3 activation and triggered STAT1-mediated pathways and apoptosis in HSC. Interestingly, this selective pro-apoptotic effect completely disappeared when STAT1 was silenced. Conditioned medium experiments showed that HSC apoptosis activated STAT3 in hepatocytes in an interleukin-6-dependent mechanism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>RPV ameliorates liver fibrosis through selective STAT1-dependent induction of apoptosis in HSC, which exert paracrinal effects in hepatocytes, thus promoting liver regeneration. RPV\u2019s actions may represent an effective strategy to treat chronic liver diseases of different aetiologies and help identify novel therapeutic targets.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2019-318372","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T17:19:22Z","timestamp":1568740762000},"page":"920-932","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":103,"title":["Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells"],"prefix":"10.1136","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-7692","authenticated-orcid":false,"given":"Alberto","family":"Mart\u00ed-Rodrigo","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alegre","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"},{"name":"FISABIO-Hospital Universitario Dr. Peset, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela B","family":"Moragrega","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Bioinformatics & Biostatistics Unit, Principe Felipe Research Center, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0918","authenticated-orcid":false,"given":"Pablo","family":"Mart\u00ed-Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Fern\u00e1ndez-Iglesias","sequence":"additional","affiliation":[{"name":"Liver Vascular Biology Research Group, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS)-CIBERehd, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-4089","authenticated-orcid":false,"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[{"name":"Liver Vascular Biology Research Group, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS)-CIBERehd, Barcelona, Spain"},{"name":"Hepatology, Department of Biomedical Research, Inselspital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezda","family":"Apostolova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan V","family":"Esplugues","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"},{"name":"FISABIO-Hospital Universitario Dr. Peset, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-1470","authenticated-orcid":false,"given":"Ana","family":"Blas-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"2025090722323433000_69.5.920.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306842"},{"key":"2025090722323433000_69.5.920.2","first-page":"812","article-title":"Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV\/hepatitis C virus-coinfected patients with liver cirrhosis","volume":"72","author":"Merli","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025090722323433000_69.5.920.3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15284336.2015.1112480","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"17","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2025090722323433000_69.5.920.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu234"},{"key":"2025090722323433000_69.5.920.5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3851\/IMP3188","article-title":"3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz\/emtricitabine\/tenofovir and rilpivirine\/emtricitabine\/tenofovir","volume":"23","author":"Gagliardini","year":"2017","journal-title":"Antivir Ther"},{"key":"2025090722323433000_69.5.920.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155842","article-title":"hEPAtic safety of Rilpivirine\/Emtricitabine\/Tenofovir disoproxil fumarate fixed-dose Single-Tablet regimen in HIV-infected patients with active hepatitis C virus infection: the hEPAtic study","volume":"11","author":"Neukam","year":"2016","journal-title":"PLoS One"},{"key":"2025090722323433000_69.5.920.7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09540121.2015.1096890","article-title":"Patient-reported outcomes in the single-tablet regimen (StAR) trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment","volume":"28","author":"Wilkins","year":"2016","journal-title":"AIDS Care"},{"key":"2025090722323433000_69.5.920.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.003"},{"key":"2025090722323433000_69.5.920.9","doi-asserted-by":"crossref","DOI":"10.1038\/srep44910","article-title":"Quantitative proteomic analysis on activated hepatic stellate cells reversion reveal STAT1 as a key regulator between liver fibrosis and recovery","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"2025090722323433000_69.5.920.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.029"},{"key":"2025090722323433000_69.5.920.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.049"},{"key":"2025090722323433000_69.5.920.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313392"},{"key":"2025090722323433000_69.5.920.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24339"},{"key":"2025090722323433000_69.5.920.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23647"},{"key":"2025090722323433000_69.5.920.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: evidence from translational studies","volume":"7","author":"de Mesquita","year":"2017","journal-title":"Sci Rep"},{"key":"2025090722323433000_69.5.920.16","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9574LSF"},{"key":"2025090722323433000_69.5.920.17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/30.1.207"},{"key":"2025090722323433000_69.5.920.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.04.002"},{"key":"2025090722323433000_69.5.920.19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/bph.12997","article-title":"Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine","volume":"172","author":"Sharma","year":"2015","journal-title":"Br J Pharmacol"},{"key":"2025090722323433000_69.5.920.20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eimc.2010.12.001","article-title":"[Management of antiretroviral drug toxicity]","volume":"29","author":"Domingo","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025090722323433000_69.5.920.21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"Hagins","year":"2018","journal-title":"HIV Med"},{"key":"2025090722323433000_69.5.920.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3268-5","article-title":"Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)","volume":"18","author":"Taramasso","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025090722323433000_69.5.920.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"2025090722323433000_69.5.920.24","first-page":"139","article-title":"Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine","volume":"15","author":"Casado","year":"2013","journal-title":"AIDS Rev"},{"key":"2025090722323433000_69.5.920.25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"2025090722323433000_69.5.920.26","unstructured":"Younossi Z , Tacke F , Arrese M , et al . Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 2018."},{"key":"2025090722323433000_69.5.920.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.011"},{"key":"2025090722323433000_69.5.920.28","doi-asserted-by":"publisher","DOI":"10.2741\/3886"},{"key":"2025090722323433000_69.5.920.29","doi-asserted-by":"crossref","unstructured":"Ambade A , Lowe P , Kodys K , et al . Pharmacological inhibition of CCR2\/5 signaling prevents and reverses alcoholinduced liver damage, steatosis and inflammation in mice. Hepatology 2018.","DOI":"10.1002\/hep.30249"},{"key":"2025090722323433000_69.5.920.30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"2025090722323433000_69.5.920.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist Cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"2025090722323433000_69.5.920.32","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090722323433000_69.5.920.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.005"},{"key":"2025090722323433000_69.5.920.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1507499112"},{"key":"2025090722323433000_69.5.920.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.07.008"},{"key":"2025090722323433000_69.5.920.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3818"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-318372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:33:50Z","timestamp":1757309630000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-318372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,3]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/gutjnl-2019-318372"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-318372","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]}}}